Associations between psychosocial risk factors and immune checkpoint inhibitor outcomes

被引：0
|
作者：
Derry-Vick, Heather
Zaemes, Jacob Peter
Ahn, Jaeil
Pascual, Lauren
Sinclaire, Brittany
Lev-Ari, Shaked
Alaoui, Adil
Sridhar, Aishwarya
Adams, David
Della Pia, Alexandra
Pecora, Andrew L.
Atkins, Michael B.
Ip, Andrew
Shah, Neil J.
机构：
[1] Hackensack Meridian Hlth, Ctr Discovery & Innovat, Nutley, NJ USA
[2] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[3] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[4] Georgetown Univ, Innovat Ctr Biomed Informat ICBI, Washington, DC USA
[5] Hackensack Meridian Sch Med, Nutley, NJ USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12134
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Risk Factors for Immune Checkpoint Inhibitor-Mediated Cardiovascular Toxicities
    Yousif, Laura I.
    Screever, Elles M.
    Versluis, Danielle
    Aboumsallem, Joseph Pierre
    Nierkens, Stefan
    Manintveld, Olivier C.
    de Boer, Rudolf A.
    Meijers, Wouter C.
    CURRENT ONCOLOGY REPORTS, 2023, 25 (07) : 753 - 763
  • [12] The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis
    Asada, Mizuho
    Mikami, Takahisa
    Niimura, Takahiro
    Zamami, Yoshito
    Uesawa, Yoshihiro
    Chuma, Masayuki
    Ishizawa, Keisuke
    ONCOLOGY, 2021, 99 (04) : 256 - 259
  • [13] Thromboembolism during immune checkpoint inhibitor therapy: frequency and risk factors
    Ide, Takayuki
    Araki, Taisuke
    Koizumi, Tomonobu
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [14] Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor
    Li, Peng
    Qin, Peng
    Fu, Xiaomin
    Zhang, Guowei
    Yan, Xiangtao
    Zhang, Mina
    Zhang, Xiaojuan
    Yang, Jinpo
    Wang, Huijuan
    Ma, Zhiyong
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (03) : 3039 - +
  • [15] Immune Checkpoint Inhibitor Therapy and Associations with Clonal Hematopoiesis
    Singh, Abhay
    Trinchant, Nuria Mencia
    Mishra, Rahul
    Arora, Kirti
    Mehta, Smit
    Kuzmanovic, Teodora
    Nikoo, Maedeh Zokaei
    Singh, Inderpreet
    Przespolewski, Amanda C.
    Swaminathan, Mahesh
    Ernstoff, Marc S.
    Dy, Grace K.
    Yan, Lunbiao
    Sinha, Eti
    Sharma, Shruti
    Hassane, Duane C.
    Griffiths, Elizabeth A.
    Wang, Eunice
    Guzman, Monica L.
    Thota, Swapna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (20)
  • [16] Associations Between Circulating Proteins and Intracardiac Immune Populations in Immune Checkpoint Inhibitor-Associated Myocarditis
    Zlotoff, Daniel
    Blum, Steven
    Ramesh, Swetha
    Kernin, Isabela
    Smith, Neal
    Sen, Pritha
    Zubiri, Leyre
    Tirard, Alice
    Nasrallah, Mazen
    Tantivit, Jessica
    Manakongtreecheep, Kasidet
    Arnold, Benjamin
    Chan, PuiYee
    Barth, Jaimie
    Juric, Dejan
    Sullivan, Ryan
    Boland, Genevieve
    Mino-Kenudson, Mari
    Stone, James R.
    Thomas, Molly F.
    Caplin, Joshua
    Reynolds, Kerry
    CIRCULATION, 2022, 146
  • [17] Incidence and Risk Factors of Venous and Arterial Thromboembolism in Immune Checkpoint Inhibitor Therapy
    Liu, Tingting
    Tang, Liang V.
    CURRENT PHARMACEUTICAL DESIGN, 2022, 28 (36) : 2950 - 2952
  • [18] Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor-Associated Pneumonitis in Patients With Lung Cancer
    Li, Xuemeng
    Yang, Fang
    Liu, Baogang
    Ye, Leiguang
    Du, Jingwen
    Fan, Xiaona
    Yu, Yue
    Li, Mengwei
    Bu, Li
    Zhang, Zhuoqi
    Xie, Lili
    Li, Wuquan
    Qi, Jiaqing
    JOURNAL OF IMMUNOTHERAPY, 2024, 47 (06) : 220 - 226
  • [19] RISK FACTORS FOR OUTCOMES OF PATIENTS WITH HISTOLOGICALLY PROVEN CHECKPOINT-INHIBITOR COLITIS
    Voth, Elida
    Saha, Srishti
    Raffals, Laura
    Pardi, Darrell
    Khanna, Sahil
    INFLAMMATORY BOWEL DISEASES, 2021, 27 : S36 - S37
  • [20] RISK FACTORS FOR OUTCOMES OF PATIENTS WITH HISTOLOGICALLY PROVEN CHECKPOINT-INHIBITOR COLITIS
    Voth, Elida
    Saha, Srishti
    Raffals, Laura
    Pardi, Darrell
    Khanna, Sahil
    GASTROENTEROLOGY, 2021, 160 (03) : S49 - S50
12345